Briefing
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
An updated analysis of IMvigor010 reported overall survival by ctDNA status for adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma. The abstract does not name the assay.
- Design: Evidence level 2
- Assay: Not named in the abstract
European UrologyPubMed 37500339DOI 10.1016/j.eururo.2023.06.007